How were Anthera Pharmaceuticals' earnings last quarter?

Anthera Pharmaceuticals, Inc. (OTCMKTS:ANTH) released its earnings results on Monday, March, 5th. The biopharmaceutical company reported ($0.73) earnings per share for the quarter, topping analysts' consensus estimates of ($0.82) by $0.09.

When did Anthera Pharmaceuticals' stock split?

Anthera Pharmaceuticals shares reverse split before market open on Monday, May 1st 2017. The 1-8 reverse split was announced on Friday, April 28th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, April 28th 2017. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.

What other stocks do shareholders of Anthera Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Anthera Pharmaceuticals investors own include Ocular Therapeutix (OCUL) , Novavax (NVAX) , Synergy Pharmaceuticals (SGYP) , Inovio Pharmaceuticals (INO) , Dynavax Technologies (DVAX) , Arena Pharmaceuticals (ARNA) , OPKO Health (OPK) , AVEO Pharmaceuticals (AVEO) , Amicus Therapeutics (FOLD) and Alibaba Group (BABA) .

How do I buy shares of Anthera Pharmaceuticals?

Shares of ANTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

OTCMKTS:ANTH

Anthera Pharmaceuticals (ANTH) Stock Price, News & Analysis

→ Now Open: Crypto emergency update (From InvestorPlace) (Ad)

Free ANTH Stock Alerts

Compare

Today's Range: N/A
50-Day Range: N/A
52-Week Range: N/A

Volume: N/A
Average Volume: N/A
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Financials SEC Filings Short Interest

Get Anthera Pharmaceuticals alerts:

Ad InvestorPlace

You’re invited: Biggest crypto event of 2024

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

About Anthera Pharmaceuticals Stock (OTCMKTS:ANTH)

Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy. The company has license agreements with Amgen, Inc., and Eli Lilly and Company. Anthera Pharmaceuticals, Inc. was founded in 2004 and is based in Houston, Texas.

Ad InvestorPlace

You’re invited: Biggest crypto event of 2024

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

ANTH Stock News Headlines

June 28, 2023 | finance.yahoo.com

MACK - Merrimack Pharmaceuticals, Inc.

May 16, 2023 | marketwatch.com

Industry Research Report on Cystic Fibrosis Drugs Market Share and Industrial Overview till 2030

April 19, 2024 | Paradigm Press (Ad)

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.

May 16, 2023 | marketwatch.com

Systemic Lupus Erythematosus (SLE) Drugs Market Updates: 2023-2030 Forecast

May 5, 2023 | marketwatch.com

2023-2030 Vasculitis Treatment Market Size (Growth and Outlook) includes Main Business Overview | with [124 Pages]

May 4, 2023 | marketwatch.com

2023-2030 Gaucher Disease Treatment Market Size (Growth and Outlook) includes Company Information | with [104 Pages]

April 28, 2023 | marketwatch.com

Gaucher Disease Treatment Market Top Key Players by 2030

April 7, 2023 | marketwatch.com

Global Cystic Fibrosis Drugs Market Size 2023 to 2026 Size and Share Survey Report

April 19, 2024 | Paradigm Press (Ad)

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

March 28, 2023 | marketwatch.com

Celiac Disease Drug Market Size and Forecast till 2030

March 10, 2023 | marketwatch.com

Cystic Fibrosis Drugs Market 2023-2028 Recent Study by Trend and Growth Analysis

March 8, 2023 | finance.yahoo.com

Infectious disease specialist Dr. Regis A. Vilchez is appointed CMO of MicuRx Pharmaceuticals, Inc.

February 26, 2023 | thestreet.com

Two Drugs, Designed To Help Patients, Actually Hurt Them

January 13, 2023 | marketwatch.com

Gaucher Disease Treatment Market Provides an In-Depth Insight of Trends and Landscape Outlook 2023-2028

January 7, 2023 | marketwatch.com

Celiac Drugs Market Trends, Business Overview, Industry Growth, and Forecast 2023 To 2028

December 17, 2022 | marketwatch.com

Gaucher Disease Treatment Market Research report forecast 2023 To 2028, Latest Industry News, Top Company Analysis, Research Methodology

October 12, 2022 | marketwatch.com

Cystic Fibrosis Drugs Market 2022 | Upcoming Trends, Recent Development, Top Manufacturers, Industry Drivers and Forecast to 2028

September 1, 2022 | apnews.com

Thryv Therapeutics Inc. Announces the Appointment of Dr. Debra Odink to President and Dr. Shi Yin Foo to the Board of Directors

August 26, 2022 | reuters.com

ANTH.PQ - Anthera Pharmaceuticals Inc | Stock Price & Latest News | Reuters

June 10, 2022 | benzinga.com

Anthera Pharmaceuticals (OTC:ANTH), Short Interest Report

May 10, 2022 | marketwatch.com

Vasculitis Treatment Market Size 2022 including Scope, Trends, Manufacturers, Growth Factors, Market Dynamics and Forecast to 2028

April 21, 2022 | bizjournals.com

The Petri Dish: Two startups get new CEOs, workforce dev coalition ramps up

April 14, 2022 | finanznachrichten.de

NervGen Pharma Corp.: NervGen Pharma Appoints Craig Thompson to the Board of Directors

April 13, 2022 | finance.yahoo.com

NervGen Pharma Appoints Craig Thompson to the Board of Directors

November 24, 2021 | finanznachrichten.de

Santhera Pharmaceuticals Holding AG: Santhera and ReveraGen Announce Positive Topline Results with Vamorolone after Completion of the VISION-DMD Study

October 26, 2021 | sg.finance.yahoo.com

Anthera Pharmaceuticals, Inc. (ANTH)

October 4, 2021 | marketwatch.com

EPI Market 2021 : Global Industry Analysis, Trends, Market Size and Forecasts Up to 2025 with Dominant Sectors and Countries Data

See More Headlines

Receive ANTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Anthera Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/05/2018
Today: 4/18/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: OTCMKTS:ANTH
CUSIP: N/A
CIK: 1316175
Web: www.anthera.com
Phone: (410) 350-1839
Fax: 510-856-5597
Employees: 21
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: 1.13

Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

Mr. Paul F. Truex M.B.A. (Age 55)
Executive Chairman
Comp: $100k
Mr. John Craig Thompson (Age 57)
CEO & Director
Comp: $715.3k
Ms. May Liu (Age 48)
Senior VP of Finance & Administration and Principal Accounting Officer
Comp: $373.44k
Dr. Paul Adams Ph.D. (Age 61)
Senior Vice President of Global Regulatory Affairs and Compliance
Joshua Caldwell
Chief Liquidating Officer

Key Competitors

View All Competitors

ANTH Stock Analysis - Frequently Asked Questions

How were Anthera Pharmaceuticals' earnings last quarter?: Anthera Pharmaceuticals, Inc. (OTCMKTS:ANTH) released its earnings results on Monday, March, 5th. The biopharmaceutical company reported ($0.73) earnings per share for the quarter, topping analysts' consensus estimates of ($0.82) by $0.09.
When did Anthera Pharmaceuticals' stock split?: Anthera Pharmaceuticals shares reverse split before market open on Monday, May 1st 2017. The 1-8 reverse split was announced on Friday, April 28th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, April 28th 2017. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.
What other stocks do shareholders of Anthera Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Anthera Pharmaceuticals investors own include Ocular Therapeutix (OCUL), Novavax (NVAX), Synergy Pharmaceuticals (SGYP), Inovio Pharmaceuticals (INO), Dynavax Technologies (DVAX), Arena Pharmaceuticals (ARNA), OPKO Health (OPK), AVEO Pharmaceuticals (AVEO), Amicus Therapeutics (FOLD) and Alibaba Group (BABA).
How do I buy shares of Anthera Pharmaceuticals?: Shares of ANTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:ANTH) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial